“Hereditary Transthyretin Amyloidosis (hATTR) Pipeline Insight, 2023” report by DelveInsight outlines a comprehensive assessment of the present clinical/non-clinical development activities and growth prospects across the Hereditary Transthyretin Amyloidosis Market.
The Hereditary Transthyretin Amyloidosis Pipeline report embraces in-depth commercial, regulatory, and Hereditary Transthyretin Amyloidosis clinical trial assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the emerging Hereditary Transthyretin Amyloidosis drugs, including the mechanism of action, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers, acquisition, funding, designations, and other product-related details.
Hereditary Transthyretin Amyloidosis (hATTR) Pipeline Analysis
The report provides insights into:
-
The report provides detailed insights into the emerging therapies for Hereditary Transthyretin Amyloidosis treatment and the aggregate therapies developed by major pharma companies.
-
It accesses the different Hereditary Transthyretin Amyloidosis therapies segmented into early-stage, mid-stage, and late-stage of clinical development.
-
It outlines the major Hereditary Transthyretin Amyloidosis companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
-
The report evaluates the Hereditary Transthyretin Amyloidosis drugs that are under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
-
It navigates the major collaborations (company-company collaborations and company-academia collaborations), licensing agreements, financing details, data presentation by the pharma giants, and regulatory approval in the Hereditary Transthyretin Amyloidosis therapeutic market.
Hereditary Transthyretin Amyloidosis (hATTR) Therapeutics Landscape
Since TTR protein is mainly produced in the liver, transplanting a new liver should almost eliminate the production of variant protein and further halt the disease progression outside the brain and eyes. Orthotopic liver transplant (OLT) is an established option for patients with early-stage disease; however, it might not eliminate the progression of the disease, because TTR produced by the transplanted liver can accumulate on the preexisting deposits. The other limitations of OLT include limited organ availability, surgical morbidity, and mortality, the need for lifelong immunosuppression, and the high cost of liver transplantation.
Recently few drugs have been approved for the treatment of hATTR. The approved therapies include inotersen (Tegsedi), patisiran (Onpattro), tafamidis meglumine (Vyndaqel), and tafamidis (Vyndamax).
To further improve the treatment outlook, several major pharma and biotech companies are developing therapies for Hereditary Transthyretin Amyloidosis (hATTR). Currently, Alnylam Pharmaceuticals is leading the therapeutics market with its Hereditary Transthyretin Amyloidosis (hATTR) drug candidates in the most advanced stage of clinical development.
Hereditary Transthyretin Amyloidosis (hATTR) Companies Actively Working in the Therapeutic Market Include:
-
Alnylam Pharmaceuticals
-
Ionis Pharmaceuticals
-
Eidos Therapeutics
-
Intellia Therapeutics
-
Corino Therapeutics
-
Novo Nordisk
And Many Others
Emerging and Marketed Hereditary Transthyretin Amyloidosis (hATTR) Drugs Covered in the Report Include:
-
Vutrisiran: Alnylam Pharmaceuticals
-
AKCEA-TTR-LRx: Ionis Pharmaceuticals
And Many More
Request the Sample PDF to Get a Better Understanding of the Emerging Drugs and Hereditary Transthyretin Amyloidosis Companies Working in the Market @
Analysis of Emerging Hereditary Transthyretin Amyloidosis Therapies by Phases
The report covers the emerging products under different phases of clinical development like –
-
Late-stage products (Phase III)
-
Mid-stage products (Phase II)
-
Early-stage product (Phase I)
-
Pre-clinical and Discovery stage candidates
-
Discontinued and inactive candidates
Route of Administration
Hereditary Transthyretin Amyloidosis (hATTR) pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
-
Oral
-
Parenteral
-
Intravenous
-
Subcutaneous
-
Topical
Molecule Type
Products have been categorized under various Molecule types such as
-
Monoclonal Antibody
-
Peptides
-
Polymer
-
Small molecule
-
Gene therapy
Learn How the Hereditary Transthyretin Amyloidosis Treatment Outlook will Evolve with the Ongoing Clinical and commercial Activities in the Therapeutic Market @
Table of Content (TOC)
1. Report Introduction
2. Executive Summary
3. Hereditary Transthyretin Amyloidosis Treatment Patterns
4. Hereditary Transthyretin Amyloidosis – DelveInsight’s Analytical Perspective
5. Therapeutic Assessment
6. Hereditary Transthyretin Amyloidosis Late Stage Products (Phase-III)
7. Hereditary Transthyretin Amyloidosis Mid-Stage Products (Phase-II)
8. Hereditary Transthyretin Amyloidosis Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Hereditary Transthyretin Amyloidosis Discontinued Products
13. Hereditary Transthyretin Amyloidosis Product Profiles
14. Major Hereditary Transthyretin Amyloidosis Companies in the Market
15. Key Products in the Hereditary Transthyretin Amyloidosis Therapeutics Segment
16. Dormant and Discontinued Products
17. Hereditary Transthyretin Amyloidosis Unmet Needs
18. Hereditary Transthyretin Amyloidosis Future Perspectives
19. Hereditary Transthyretin Amyloidosis Analyst Review
20. Appendix
21. Report Methodology
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Download Sample PDF to Explore the Key Offerings of the Report:
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Other Trending Healthcare Reports By DelveInsight
“Migraine Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Migraine market size, share, trends, and growth analysis in the seven major markets (i.e. the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. Moreover, it also covers the current treatment practices, emerging drugs, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the Migraine market.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/